advertisement
Mogi M 24
Showing records 1 to 24 | Display all abstracts from Mogi M76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Prasanna G
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716
77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Stacy R; Huttner K
American Journal of Ophthalmology 2018; 192: 113-123
76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Ferrara L
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716
77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Watts J
American Journal of Ophthalmology 2018; 192: 113-123
76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Adams C
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716
77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Peace J
American Journal of Ophthalmology 2018; 192: 113-123
76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Ehara T
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716
77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Wirta D
American Journal of Ophthalmology 2018; 192: 113-123
76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Li B; Yang L
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716
77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Walters T; Sall K
American Journal of Ophthalmology 2018; 192: 113-123
76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Xiang C; Ng CTH
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716
77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Seaman J
American Journal of Ophthalmology 2018; 192: 113-123
76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Kim S
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716
77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Ni X; Prasanna G
American Journal of Ophthalmology 2018; 192: 113-123
76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Towler C; Topley T
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716
77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Mogi M; Adams C
American Journal of Ophthalmology 2018; 192: 113-123
76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
McAllister C; Ghosh M
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716
77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Yan JH; Wald M
American Journal of Ophthalmology 2018; 192: 113-123
76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Newton R
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716
77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
He Y
American Journal of Ophthalmology 2018; 192: 113-123
76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Stacy R; Rice DS
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716
77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Newton R
American Journal of Ophthalmology 2018; 192: 113-123
76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Mogi M
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716
77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Kolega R; Grosskreutz C
American Journal of Ophthalmology 2018; 192: 113-123
